The Experts below are selected from a list of 237 Experts worldwide ranked by ideXlab platform
Hyun Chae Jung - One of the best experts on this subject based on the ideXlab platform.
-
effect of the cyp2c19 polymorphism on the eradication rate of helicobacter pylori infection by 7 day triple therapy with regular proton pump Inhibitor Dosage
Journal of Gastroenterology and Hepatology, 2008Co-Authors: Jung Mook Kang, Young Soo Park, In Jin Chang, In Sung Song, Hyun Chae JungAbstract:Background and Aim: Proton pump Inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. Methods: A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing. Results: The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively. Conclusion: The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.
-
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump Inhibitor Dosage.
Journal of gastroenterology and hepatology, 2008Co-Authors: Jung Mook Kang, Young Soo Park, In Jin Chang, In Sung Song, Hyun Chae JungAbstract:Proton pump Inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing. The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively. The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.
Manuele Furnari - One of the best experts on this subject based on the ideXlab platform.
-
sa1351 voluntary and controlled weight loss can reduce symptoms and allow a lowering of proton pump Inhibitor Dosage in patients with gastroesophageal reflux disease a case control study
Gastroenterology, 2014Co-Authors: Nicola De Bortoli, G Guidi, Edoardo Savarino, Lorenzo Bertani, Riccardo Franchi, Irene Martinucci, Lorenzo Macchia, L Ceccarelli, S Russo, Manuele FurnariAbstract:Voluntary and Controlled Weight Loss Can Reduce Symptoms and Allow a Lowering of Proton Pump Inhibitor Dosage in Patients With Gastroesophageal Reflux Disease. A Case-Control Study Nicola de Bortoli, Giada Guidi, Edoardo Savarino, Lorenzo Bertani, Riccardo Franchi, Irene Martinucci, Lorenzo Macchia, Linda Ceccarelli, Salvatore Russo, Manuele Furnari, Massimo Bellini, Vincenzo Savarino, Santino Marchi
Jung Mook Kang - One of the best experts on this subject based on the ideXlab platform.
-
effect of the cyp2c19 polymorphism on the eradication rate of helicobacter pylori infection by 7 day triple therapy with regular proton pump Inhibitor Dosage
Journal of Gastroenterology and Hepatology, 2008Co-Authors: Jung Mook Kang, Young Soo Park, In Jin Chang, In Sung Song, Hyun Chae JungAbstract:Background and Aim: Proton pump Inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. Methods: A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing. Results: The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively. Conclusion: The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.
-
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump Inhibitor Dosage.
Journal of gastroenterology and hepatology, 2008Co-Authors: Jung Mook Kang, Young Soo Park, In Jin Chang, In Sung Song, Hyun Chae JungAbstract:Proton pump Inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing. The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively. The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.
Nicola De Bortoli - One of the best experts on this subject based on the ideXlab platform.
-
sa1351 voluntary and controlled weight loss can reduce symptoms and allow a lowering of proton pump Inhibitor Dosage in patients with gastroesophageal reflux disease a case control study
Gastroenterology, 2014Co-Authors: Nicola De Bortoli, G Guidi, Edoardo Savarino, Lorenzo Bertani, Riccardo Franchi, Irene Martinucci, Lorenzo Macchia, L Ceccarelli, S Russo, Manuele FurnariAbstract:Voluntary and Controlled Weight Loss Can Reduce Symptoms and Allow a Lowering of Proton Pump Inhibitor Dosage in Patients With Gastroesophageal Reflux Disease. A Case-Control Study Nicola de Bortoli, Giada Guidi, Edoardo Savarino, Lorenzo Bertani, Riccardo Franchi, Irene Martinucci, Lorenzo Macchia, Linda Ceccarelli, Salvatore Russo, Manuele Furnari, Massimo Bellini, Vincenzo Savarino, Santino Marchi
Young Soo Park - One of the best experts on this subject based on the ideXlab platform.
-
effect of the cyp2c19 polymorphism on the eradication rate of helicobacter pylori infection by 7 day triple therapy with regular proton pump Inhibitor Dosage
Journal of Gastroenterology and Hepatology, 2008Co-Authors: Jung Mook Kang, Young Soo Park, In Jin Chang, In Sung Song, Hyun Chae JungAbstract:Background and Aim: Proton pump Inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. Methods: A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing. Results: The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively. Conclusion: The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.
-
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump Inhibitor Dosage.
Journal of gastroenterology and hepatology, 2008Co-Authors: Jung Mook Kang, Young Soo Park, In Jin Chang, In Sung Song, Hyun Chae JungAbstract:Proton pump Inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy. A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing. The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively. The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.